IRIS UniCatt

Colafigli, Manuela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.767
NA - Nord America 2.754
AS - Asia 1.649
SA - Sud America 355
AF - Africa 43
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 3
AN - Antartide 1
Totale 7.577
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.677
DE - Germania 876
SG - Singapore 777
CN - Cina 479
FR - Francia 379
SE - Svezia 367
PL - Polonia 329
BR - Brasile 290
UA - Ucraina 234
IT - Italia 189
GB - Regno Unito 122
IE - Irlanda 99
IN - India 81
ID - Indonesia 65
VN - Vietnam 64
FI - Finlandia 55
TR - Turchia 54
CA - Canada 46
RU - Federazione Russa 40
AR - Argentina 30
HK - Hong Kong 24
JP - Giappone 21
MX - Messico 20
BD - Bangladesh 17
ZA - Sudafrica 17
BE - Belgio 14
IQ - Iraq 11
ES - Italia 10
LT - Lituania 9
IR - Iran 8
VE - Venezuela 8
AT - Austria 7
MA - Marocco 7
NL - Olanda 7
CO - Colombia 5
CZ - Repubblica Ceca 5
EC - Ecuador 5
EU - Europa 5
IL - Israele 5
JO - Giordania 5
PH - Filippine 5
JM - Giamaica 4
KZ - Kazakistan 4
PK - Pakistan 4
PY - Paraguay 4
UY - Uruguay 4
AL - Albania 3
BG - Bulgaria 3
CH - Svizzera 3
CL - Cile 3
DZ - Algeria 3
EG - Egitto 3
GR - Grecia 3
KR - Corea 3
PE - Perù 3
SA - Arabia Saudita 3
TN - Tunisia 3
AU - Australia 2
AZ - Azerbaigian 2
BO - Bolivia 2
CI - Costa d'Avorio 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GE - Georgia 2
HN - Honduras 2
KE - Kenya 2
KG - Kirghizistan 2
NO - Norvegia 2
PT - Portogallo 2
RS - Serbia 2
AM - Armenia 1
AO - Angola 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BW - Botswana 1
CR - Costa Rica 1
CY - Cipro 1
EE - Estonia 1
IM - Isola di Man 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
MM - Myanmar 1
MY - Malesia 1
NG - Nigeria 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PA - Panama 1
PS - Palestinian Territory 1
QA - Qatar 1
RW - Ruanda 1
SR - Suriname 1
TW - Taiwan 1
UZ - Uzbekistan 1
Totale 7.577
Salva come PNG Salva come JPEG
Città #
Chandler 469
Singapore 344
Kraków 317
Ashburn 259
Jacksonville 163
New York 143
San Mateo 120
Dublin 97
Nanjing 90
Beijing 82
Dearborn 73
Houston 65
Wilmington 63
Jakarta 59
Los Angeles 58
Ann Arbor 54
Milan 50
Nürnberg 47
Boston 46
Lawrence 45
Cattolica 43
Dallas 41
Izmir 41
Redmond 41
Nanchang 37
Woodbridge 32
Munich 31
Redwood City 29
Hefei 27
Hong Kong 23
Lancaster 23
Bremen 21
Frankfurt am Main 21
Hanoi 21
Ho Chi Minh City 20
Moscow 20
Changsha 19
Fairfield 19
Ottawa 19
Buffalo 17
Seattle 17
University Park 17
Chicago 16
Shenyang 16
São Paulo 16
Tokyo 16
Atlanta 15
Princeton 15
Boardman 14
Brussels 14
Hebei 13
Kunming 13
London 12
Mountain View 12
The Dalles 12
Fremont 11
Guangzhou 11
Marseille 11
Montreal 11
Norwalk 11
San Francisco 11
Brooklyn 10
Düsseldorf 10
Jinan 10
Leawood 10
Rome 10
Santa Clara 10
Shanghai 10
Augusta 9
Falls Church 9
Jiaxing 9
Johannesburg 9
Lauterbourg 9
Toronto 9
Verona 9
Hangzhou 8
Nuremberg 8
Poplar 8
Portsmouth 8
Pune 8
Warsaw 8
Denver 7
Orem 7
Porto Alegre 7
Tianjin 7
Washington 7
Helsinki 6
Manchester 6
Phoenix 6
Rio de Janeiro 6
Simi Valley 6
Zhengzhou 6
Amman 5
Ankara 5
Cambridge 5
Campinas 5
Changchun 5
Chennai 5
Guarulhos 5
Kent 5
Totale 3.765
Salva come PNG Salva come JPEG
Nome #
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 253
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 212
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 191
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 188
Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance 182
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 180
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 179
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 177
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 170
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. 162
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 162
Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. 161
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 158
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 150
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study 149
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 144
Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar year: a cohort study 143
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 142
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 140
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 138
Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction? 134
Cardiovascular risk factors and carotid intima-media thickness are associated with low cognitive performance in HIV-infected patients 134
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study 134
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 134
Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1 133
HIV-infected patients show impaired cellular immune response to influenza vaccination, compared to healthy subjects 132
Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients 131
Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. 128
Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. 127
HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects 127
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. 124
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group 123
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: A multicenter observational study 122
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients 121
Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. 120
Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients 119
Prevalence of transmitted HIV-1 drug resistance in HIV-1 infected patients in Italy: evolution over 12 years and predictors 118
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 118
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 117
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 115
Long term follow-up of Nevirapine-treated patients in a single centre cohort 113
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 113
Exploratory analysis for the evaluation of estimated glomerular filtration rate, cholesterol and triglycerides after switching from tenofovir/emtricitabine plus atazanavir/ritonavir (ATV/r) to abacavir/lamivudine plus ATV/r in patients with preserved renal function 111
Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine 108
Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors 105
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis 105
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort 103
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 102
Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study 99
Interpretation systems for genotypic drug resistance of HIV-1 98
Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors, non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: a multicenter retrospective cohort study 92
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study 86
Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy 82
Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian Cohort 76
Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study 75
Survival in HIV-infected patients after a cancer diagnosis in the cART era: Results of an Italian multicenter study 71
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015 69
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 66
Combining epidemiological and genetic networks signifies the importance of early treatment in HIV-1 transmission 61
Totale 7.627
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.874
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.874
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021292 0 0 0 0 0 31 49 8 82 16 91 15
2021/2022555 51 52 13 41 24 28 9 104 17 46 72 98
2022/20231.141 170 177 82 185 82 143 25 92 129 5 38 13
2023/2024570 19 151 9 59 23 169 17 4 6 9 69 35
2024/2025991 17 29 70 48 135 44 20 56 155 99 173 145
2025/20261.447 409 55 157 298 509 19 0 0 0 0 0 0
Totale 7.627